Skip to main content
Download PDF

For robust big data analyses: a collection of 150 important pro-metastatic genes

Chinese Journal of Cancer volume 36, Article number: 16 (2017) Cite this article

Abstract

Metastasis is the greatest contributor to cancer-related death. In the era of precision medicine, it is essential to predict and to prevent the spread of cancer cells to significantly improve patient survival. Thanks to the application of a variety of high-throughput technologies, accumulating big data enables researchers and clinicians to identify aggressive tumors as well as patients with a high risk of cancer metastasis. However, there have been few large-scale gene collection studies to enable metastasis-related analyses. In the last several years, emerging efforts have identified pro-metastatic genes in a variety of cancers, providing us the ability to generate a pro-metastatic gene cluster for big data analyses. We carefully selected 285 genes with in vivo evidence of promoting metastasis reported in the literature. These genes have been investigated in different tumor types. We used two datasets downloaded from The Cancer Genome Atlas database, specifically, datasets of clear cell renal cell carcinoma and hepatocellular carcinoma, for validation tests, and excluded any genes for which elevated expression level correlated with longer overall survival in any of the datasets. Ultimately, 150 pro-metastatic genes remained in our analyses. We believe this collection of pro-metastatic genes will be helpful for big data analyses, and eventually will accelerate anti-metastasis research and clinical intervention.

Background

Cancer metastasis is the greatest cause of death in almost all types of malignancies [1]. Multiple factors from the tumor and the host contribute to the formation and progression of distant secondary tumors [1, 2], and most of the mechanistic studies to date have mainly focused on the metastatic potential of tumor cells. It is believed that the metastasis of single cancer cells begins with the cells gaining the ability to migrate and invade. The cancer cells can gain motility in several ways, including epithelial-mesenchymal transition (EMT) and fusion of cancer cells to highly mobile bone marrow-derived cells [3, 4]. In the metastases formed by clusters of tumor cells, EMT may not be necessary [5]; however, the layer of endothelial cells enveloping the entire tumor cluster/embolus seems critical for the survival of tumor clusters [6].

The ability to identify cancer patients with a high risk of metastasis is essential in the era of precision medicine. In addition to applying clinicopathologic parameter combination, also known as clinical prognostic classifiers in some circumstances, molecular profiling based on high-throughput technologies is expected to allow for a more accurate and robust prognostic prediction of metastatic potential in patients. How to effectively analyze big data generated from high-throughput screening is an emerging issue for many bioinformaticians. We hypothesize that, with optimal weighting on the impact of each individual gene, a collection of key pro-metastatic genes could be useful to generate a prognostic tool to identify the metastatic potential of a specific tumor and novel signaling pathways underlying metastasis.

Main text

The increased investigation of cancer metastasis in recent years has identified over 200 pro-metastatic genes. In this review, we aim to identify a group of key pro-metastatic genes with in vivo functional evidence and reasonable clinical relevance for application to big data analyses.

Figure 1 summarizes the analytic procedure of this review. First, we carefully selected 285 genes from the literature through searching PubMed based on the following criteria: (1) author-provided evidence of promoting migration and/or invasion of cancer cells; (2) author-provided evidence of promoting metastasis in vivo using animal models; (3) when a gene has been reported as pro-metastatic in several articles, all articles reporting the link were reviewed, and the most convincing studies are listed as the key references in Table 1. In addition, we applied survival analyses as validation tests using the publicly available TCGA datasets (threshold = 0.05). For analyses of clear cell renal cell carcinoma (ccRCC), the mRNA expression data of 72 non-cancerous kidney tissues and 539 tumors [clear cell kidney carcinoma (KIRC) in the TCGA database] were downloaded. For analyses of hepatocellular carcinoma (HCC), the mRNA expression data of 50 non-cancerous liver tissues and 374 tumors [liver hepatocellular carcinoma (LIHC) in the TCGA database] were used. Normalization was performed using the DESeq method (Version 1.26.0). For each individual gene, the median expression level was used as a cut-off value to separate the patients into high and low expression groups. Genes were excluded if their elevated expression significantly associated with better patient prognosis in any patient cohort. Finally, 150 genes passed the tests and are listed in Table 1. Among them, 79 genes have significant prognostic values in the ccRCC patient cohort, 35 genes have significant prognostic values in the HCC cohort, and 23 genes have significant prognostic values in both cohorts.

Fig. 1
figure1

A schematic illustration of the study design and findings

Full size image
Table 1 The list of 150 pro-metastatic genes with clinical relevance and key references
Full size table

Although different tumor types are believed to rely on different molecular mechanisms for metastasis, 23 common pro-metastatic genes have been identified in our analyses, associating with poor prognosis in both cancer types. Among them, we are most interested in 11 genes that are not only statistically significant in terms of prognostic impact but also associated with distinct overall survival curves in both cohorts, suggesting the genes’ profound biological impacts on tumor progression. For the other 12 genes, although their biological impact on tumor progression were found to be significant in log-rank tests in both cohorts, the survival curves of high versus low expression groups crossed at some time points. The 11 most interesting genes are BIRC5 (Survivin), CXCL1, CXCL8 (IL8), E2F1, ETV4, EZH2, MMP1, MMP9, MYB, PTTG1, and YBX1. Figure 2 shows the survival curves of patients with either ccRCC or HCC expressing these 11 genes. Our findings suggest that different tumor types may partially share some common metastatic mechanisms, therefore strengthening the rationale of applying the list of 150 pro-metastatic genes to big data analyses. Interestingly, 4 of these 11 genes encode secreted proteins, namely, CXCL1, CXCL8, MMP1, and MMP9, which are ideal pharmaceutical targets for blocking cancer metastasis.

Fig. 2
figure2

The survival curves of two cohorts of cancer patients comparing the mRNA expression levels of 11 genes. The data were retrieved from The Cancer Genome Atlas (TCGA) database. The survival curves were plotted using the Kaplan–Meier method and compared using the log-rank test. Consistently, among all 11 genes presented in this figure, elevated gene expression levels significantly associate with shorter overall patient survival (P < 0.05) in both tumor types. ccRCC clear cell renal cell carcinoma, HCC hepatocellular carcinoma

Full size image

Although not covered in this review article, emerging data regarding the regulatory roles of non-coding RNA in metastasis have linked different pro-metastatic genes to forming signaling cascades [7–9]. Further investigation into the roles of non-coding RNA in metastasis is warranted.

Conclusions

In summary, we present here a collection of 150 important pro-metastatic genes for big data analyses. We expect more key molecules to be identified and validated in the near future to be included in the list, thereby accelerating the efforts in preventing and treating cancer metastasis.

References

  1. 1.

    Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16(4):201–18.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Li W, Shen LJ, Chen T, Sun XQ, Zhang Y, Wu M, et al. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study. Chin J Cancer. 2016;35(1):75.

    PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Pawelek JM. Fusion of bone marrow-derived cells with cancer cells: metastasis as a secondary disease in cancer. Chin J Cancer. 2014;33(3):133–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Savagner P. Epithelial-mesenchymal transitions: from cell plasticity to concept elasticity. Curr Top Dev Biol. 2015;112:273–300.

    PubMed  Article  Google Scholar 

  5. 5.

    Seton-Rogers S. Epithelial-mesenchymal transition: untangling EMT’s functions. Nat Rev Cancer. 2016;16(1):1.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Ding T, Xu J, Zhang Y, Guo RP, Wu WC, Zhang SD, et al. Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer. 2011;117(21):4878–89.

    PubMed  Article  Google Scholar 

  7. 7.

    Jiang C, Li X, Zhao H, Liu H. Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. Mol Cancer. 2016;15(1):62.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Sun R, Qin C, Jiang B, Fang S, Pan X, Peng L, et al. Down-regulation of MALAT1 inhibits cervical cancer cell invasion and metastasis by inhibition of epithelial-mesenchymal transition. Mol BioSyst. 2016;12(3):952–62.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, et al. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 2015;34(1):28–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74(18):5229–43.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, et al. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res. 2016;76(15):4372–82.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res. 2011;71(22):7091–102.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, et al. AKT1 activation promotes development of melanoma metastases. Cell Rep. 2015;13(5):898–905.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci USA. 2010;107(14):6340–5.

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Investig. 2011;121(11):4526–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Dey S, Sayers CM, Verginadis II, Lehman SL, Cheng Y, Cerniglia GJ, et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J Clin Investig. 2015;125(7):2592–608.

    PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA. 2014;111(37):13373–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J. 2011;30(21):4500–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Choi S, Chen Z, Tang LH, Fang Y, Shin SJ, Panarelli NC, et al. Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nat Commun. 2016;7:10384.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller WJ, et al. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res. 2013;73(2):745–55.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, et al. Survivin promotion of melanoma metastasis requires upregulation of alpha5 integrin. Carcinogenesis. 2013;34(9):2137–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Kong LM, Liao CG, Zhang Y, Xu J, Li Y, Huang W, et al. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. Cancer Res. 2014;74(14):3764–78.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014;74(13):3454–65.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, et al. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 2011;71(3):832–41.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130–3.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Yu S, Duan J, Zhou Z, Pang Q, Wuyang J, Liu T, et al. A critical role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in vitro and in vivo. Cancer Biol Ther. 2008;7(7):1037–43.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci USA. 2012;109(51):E3588–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Su J, Wu S, Wu H, Li L, Guo T. CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/beta-catenin-FoxM1-Twist signaling. Mol Carcinog. 2015;55(12):1962–73.

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA. 2011;108(4):1379–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res. 2005;65(19):8809–17.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R, et al. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 2010;29(24):4106–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, et al. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 2016;7:11418.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Investig. 2010;120(4):1178–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, et al. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res. 2015;75(3):487–96.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Sharma RK, Chheda ZS, Das Purkayastha BP, Gomez-Gutierrez JG, Jala VR, Haribabu B. A spontaneous metastasis model reveals the significance of claudin-9 overexpression in lung cancer metastasis. Clin Exp Metastasis. 2016;33(3):263–75.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Blanco MA, LeRoy G, Khan Z, Aleckovic M, Zee BM, Garcia BA, et al. Global secretome analysis identifies novel mediators of bone metastasis. Cell Res. 2012;22(9):1339–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Englund E, Bartoschek M, Reitsma B, Jacobsson L, Escudero-Esparza A, Orimo A, et al. Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer. Oncogene. 2016;35(43):5585–96.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Liu Y, Amin EB, Mayo MW, Chudgar NP, Bucciarelli PR, Kadota K, et al. CK2alpha’ drives lung cancer metastasis by targeting BRMS1 nuclear export and degradation. Cancer Res. 2016;76(9):2675–86.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Muller S, et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA. 2010;107(6):2497–502.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Lee JH, Kim HN, Kim KO, Jin WJ, Lee S, Kim HH, et al. CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res. 2012;72(13):3175–86.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, et al. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis. 2012;33(7):1302–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Choi YH, Burdick MD, Strieter BA, Mehrad B, Strieter RM. CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells. Mol Cancer Res. 2014;12(1):38–47.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Rennhack J, Andrechek E. Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. Oncoscience. 2015;2(10):867–71.

    PubMed  PubMed Central  Google Scholar 

  45. 45.

    Fujimura K, Choi S, Wyse M, Strnadel J, Wright T, Klemke R. Eukaryotic translation initiation factor 5A (EIF5A) regulates pancreatic cancer metastasis by modulating RhoA and Rho-associated kinase (ROCK) protein expression levels. J Biol Chem. 2015;290(50):29907–19.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, et al. ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1 + CD11b + Myeloid-Derived suppressor cells. PLoS Biol. 2015;13(12):e1002330.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47.

    Santiago-Medina M, Yang J. MENA promotes tumor-intrinsic metastasis through ECM remodeling and haptotaxis. Cancer Discov. 2016;6(5):474–6.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Leblanc R, Lee SC, David M, Bordet JC, Norman DD, Patil R, et al. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood. 2014;124(20):3141–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, et al. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci USA. 2013;110(37):E3506–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and snail to inhibit E-cadherin. Oncogene. 2012;31(5):583–94.

    CAS  PubMed  Google Scholar 

  51. 51.

    Weekes D, Kashima TG, Zandueta C, Perurena N, Thomas DP, Sunters A, et al. Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1. Oncogene. 2016;35(22):2948.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Berger T, Ueda T, Arpaia E, Chio II, Shirdel EA, Jurisica I, et al. Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model. Oncogene. 2013;32(41):4989–94.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci USA. 2013;110(13):5139–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013;57(2):610–24.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, et al. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-beta-dependent cancer metastasis. J Clin Investig. 2014;124(2):564–79.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Xia L, Huang W, Tian D, Zhang L, Qi X, Chen Z, et al. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. Hepatology. 2014;59(3):958–73.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 2014;159(4):844–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Gumireddy K, Li A, Kossenkov AV, Sakurai M, Yan J, Li Y, et al. The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis. Nat Commun. 2016;7:10715.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Li C, Wang J, Kong J, Tang J, Wu Y, Xu E, et al. GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 2016;7(1):860–72.

    PubMed  Google Scholar 

  60. 60.

    Lin TC, Liu YP, Chan YC, Su CY, Lin YF, Hsu SL, et al. Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis. J Pathol. 2015;237(1):50–61.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, et al. 14-3-3zeta turns TGF-beta’s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015;27(2):177–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell. 2016;30(3):444–58.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Li W, Ai N, Wang S, Bhattacharya N, Vrbanac V, Collins M, et al. GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proc Natl Acad Sci USA. 2014;111(4):1521–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Ni P, Zhang Y, Liu Y, Lin X, Su X, Lu H, et al. HMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis. Int J Clin Exp Pathol. 2015;8(12):15940–6.

    PubMed  PubMed Central  Google Scholar 

  65. 65.

    Du YC, Chou CK, Klimstra DS, Varmus H. Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis. Proc Natl Acad Sci USA. 2011;108(40):16753–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Kim YR, Kim IJ, Kang TW, Choi C, Kim KK, Kim MS, et al. HOXB13 downregulates intracellular zinc and increases NF-kappaB signaling to promote prostate cancer metastasis. Oncogene. 2014;33(37):4558–67.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Liu S, Jin K, Hui Y, Fu J, Jie C, Feng S, et al. HOXB7 promotes malignant progression by activating the TGFbeta signaling pathway. Cancer Res. 2015;75(4):709–19.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009;138(1):51–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Gumireddy K, Li A, Kossenkov AV, Cai KQ, Liu Q, Yan J, et al. ID1 promotes breast cancer metastasis by S100A9 regulation. Mol Cancer Res. 2014;12(9):1334–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012;2(8):722–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua YX, et al. IGFBP2 activates the NF-kappaB pathway to drive epithelial-mesenchymal transition and invasive character in pancreatic ductal adenocarcinoma. Cancer Res. 2016;76(22):6543–54.

    CAS  Article  Google Scholar 

  72. 72.

    Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, et al. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res. 2014;20(9):2276–88.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Zaynagetdinov R, Sherrill TP, Gleaves LA, McLoed AG, Saxon JA, Habermann AC, et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015;75(8):1624–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Oh K, Moon HG, Lee DS, Yoo YB. Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells. Lab Anim Res. 2015;31(4):188–97.

    PubMed  PubMed Central  Article  Google Scholar 

  75. 75.

    Rao F, Xu J, Fu C, Cha JY, Gadalla MM, Xu R, et al. Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. Proc Natl Acad Sci USA. 2015;112(6):1773–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Zhou B, Gibson-Corley KN, Herndon ME, Sun Y, Gustafson-Wagner E, Teoh-Fitzgerald M, et al. Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol Cancer Res. 2014;12(1):143–54.

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res. 2010;70(12):5147–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, et al. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFbeta signaling pathway. Cancer Res. 2015;75(16):3302–13.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Cho SG, Wang Y, Rodriguez M, Tan K, Zhang W, Luo J, et al. Haploinsufficiency in the prometastasis Kiss1 receptor Gpr54 delays breast tumor initiation, progression, and lung metastasis. Cancer Res. 2011;71(20):6535–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Lu H, Hu L, Yu L, Wang X, Urvalek AM, Li T, et al. KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer. Oncogene. 2014;33(22):2909–17.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    Weinspach D, Seubert B, Schaten S, Honert K, Sebens S, Altevogt P, et al. Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clin Exp Metastasis. 2014;31(1):87–100.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, et al. Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS ONE. 2013;8(2):e55714.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS, Kuo PL. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis. 2013;34(6):1370–81.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012;72(22):5757–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Cox TR, Gartland A, Erler JT. Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis. Cancer Res. 2016;76(2):188–92.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011;71(5):1561–72.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, et al. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep. 2014;6(1):141–54.

    CAS  PubMed  Article  Google Scholar 

  88. 88.

    Wu GJ, Fu P, Wang SW, Wu MW. Enforced expression of MCAM/MUC18 increases in vitro motility and invasiveness and in vivo metastasis of two mouse melanoma K1735 sublines in a syngeneic mouse model. Mol Cancer Res. 2008;6(11):1666–77.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Firon M, Shaharabany M, Altstock RT, Horev J, Abramovici A, Resau JH, et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene. 2000;19(20):2386–97.

    CAS  PubMed  Article  Google Scholar 

  90. 90.

    Wu K, Fukuda K, Xing F, Zhang Y, Sharma S, Liu Y, et al. Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer. J Biol Chem. 2015;290(15):9842–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. 91.

    Tatti O, Gucciardo E, Pekkonen P, Holopainen T, Louhimo R, Repo P, et al. MMP16 mediates a proteolytic switch to promote cell-cell adhesion, collagen alignment, and lymphatic invasion in melanoma. Cancer Res. 2015;75(10):2083–94.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Chen X, Su Y, Fingleton B, Acuff H, Matrisian LM, Zent R, et al. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int J Cancer. 2005;116(1):52–61.

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Deng L, Yang H, Tang J, Lin Z, Yin A, Gao Y, et al. Inhibition of MTA1 by ERalpha contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis. J Exp Clin Cancer Res. 2015;34:128.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  94. 94.

    Zhang B, Zhang H, Shen G. Metastasis-associated protein 2 (MTA2) promotes the metastasis of non-small-cell lung cancer through the inhibition of the cell adhesion molecule Ep-CAM and E-cadherin. Jpn J Clin Oncol. 2015;45(8):755–66.

    PubMed  Article  Google Scholar 

  95. 95.

    Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, et al. c-Myb enhances breast cancer invasion and metastasis through the Wnt/beta-Catenin/Axin2 pathway. Cancer Res. 2016;76(11):3364–75.

    CAS  PubMed  Article  Google Scholar 

  96. 96.

    Shoshan E, Braeuer RR, Kamiya T, Mobley AK, Huang L, Vasquez ME, et al. NFAT1 directly regulates IL8 and MMP3 to promote melanoma tumor growth and metastasis. Cancer Res. 2016;76(11):3145–55.

    CAS  PubMed  Article  Google Scholar 

  97. 97.

    Fung TM, Ng KY, Tong M, Chen JN, Chai S, Chan KT, et al. Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation. J Pathol. 2016;239(3):309–19.

    CAS  PubMed  Article  Google Scholar 

  98. 98.

    Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, et al. Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci USA. 2016;113(2):E172–81.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    Choi EB, Yang AY, Kim SC, Lee J, Choi JK, Choi C, et al. PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair. Oncogene. 2016;35(35):4569–79.

    CAS  PubMed  Article  Google Scholar 

  100. 100.

    Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533(7604):493–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  101. 101.

    Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, Davis CA, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell. 2014;157(2):382–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  102. 102.

    Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 2010;177(2):1004–16.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, et al. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene. 2014;33(28):3707–16.

    CAS  PubMed  Article  Google Scholar 

  104. 104.

    Samanta D, Park Y, Andrabi SA, Shelton LM, Gilkes DM, Semenza GL. PHGDH expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis. Cancer Res. 2016;76(15):4430–42.

    CAS  PubMed  Article  Google Scholar 

  105. 105.

    De Semir D, Nosrati M, Bezrookove V, Dar AA, Federman S, Bienvenu G, et al. Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proc Natl Acad Sci USA. 2012;109(18):7067–72.

    PubMed  PubMed Central  Article  Google Scholar 

  106. 106.

    Bao YN, Cao X, Luo DH, Sun R, Peng LX, Wang L, et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014;13(12):1958–69.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  107. 107.

    Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, et al. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol. 2010;119(2):337–44.

    CAS  PubMed  Article  Google Scholar 

  108. 108.

    Zhang M, Dai C, Zhu H, Chen S, Wu Y, Li Q, et al. Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem. 2011;357(1–2):387–95.

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Takano S, Reichert M, Bakir B, Das KK, Nishida T, Miyazaki M, et al. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev. 2016;30(2):233–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  110. 110.

    Song ZB, Ni JS, Wu P, Bao YL, Liu T, Li M, et al. Testes-specific protease 50 promotes cell invasion and metastasis by increasing NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Death Dis. 2015;6:e1703.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Liao YC, Ruan JW, Lua I, Li MH, Chen WL, Wang JR, et al. Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene. 2012;31(25):3086–97.

    CAS  PubMed  Article  Google Scholar 

  112. 112.

    Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, et al. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 2013;34(4):803–11.

    CAS  PubMed  Article  Google Scholar 

  113. 113.

    Wang T, Gilkes DM, Takano N, Xiang L, Luo W, Bishop CJ, et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA. 2014;111(31):E3234–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  114. 114.

    Teng Y, Qin H, Bahassan A, Bendzunas NG, Kennedy EJ, Cowell JK. The WASF3-NCKAP1-CYFIP1 complex is essential for breast cancer metastasis. Cancer Res. 2016;76(17):5133–42.

    CAS  PubMed  Article  Google Scholar 

  115. 115.

    O’Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29(1):34–44.

    PubMed  Article  CAS  Google Scholar 

  116. 116.

    Mora N, Rosales R, Rosales C. R-Ras promotes metastasis of cervical cancer epithelial cells. Cancer Immunol Immunother. 2007;56(4):535–44.

    CAS  PubMed  Article  Google Scholar 

  117. 117.

    Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, et al. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell. 2015;161(6):1345–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  118. 118.

    Dahlmann M, Kobelt D, Walther W, Mudduluru G, Stein U. S100A4 in cancer metastasis: Wnt signaling-driven interventions for metastasis restriction. Cancers (Basel). 2016;8(6):56.

    Article  Google Scholar 

  119. 119.

    Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML, et al. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 2011;17(7–8):709–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. 120.

    Luchino J, Hocine M, Amoureux MC, Gibert B, Bernet A, Royet A, et al. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell. 2013;24(5):673–85.

    CAS  PubMed  Article  Google Scholar 

  121. 121.

    Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532(7598):250–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122.

    Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, et al. Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Res. 2014;74(24):7357–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  123. 123.

    Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, et al. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res. 2009;15(22):6820–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Ding X, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor beta (TGF-beta) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem. 2013;288(15):10241–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Huang W, Chen Z, Shang X, Tian D, Wang D, Wu K, et al. Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1. Hepatology. 2015;61(6):1920–33.

    CAS  PubMed  Article  Google Scholar 

  126. 126.

    Zhou Y, Wang X, Huang Y, Chen Y, Zhao G, Yao Q, et al. Down-regulated SOX4 expression suppresses cell proliferation, metastasis and induces apoptosis in Xuanwei female lung cancer patients. J Cell Biochem. 2015;116(6):1007–18.

    CAS  PubMed  Article  Google Scholar 

  127. 127.

    Tiwari R, Pandey SK, Goel S, Bhatia V, Shukla S, Jing X, et al. SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis. 2015;4:e162.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  128. 128.

    Schmid F, Wang Q, Huska MR, Andrade-Navarro MA, Lemm M, Fichtner I, et al. SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival. Oncogene. 2016;35(46):5942–52.

    CAS  PubMed  Article  Google Scholar 

  129. 129.

    Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011;32(4):477–87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  130. 130.

    Ke L, Xiang Y, Guo X, Lu J, Xia W, Yu Y, et al. c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3 K/Akt signaling pathway: a new and promising target for NPC. Oncotarget. 2016;7(19):28340–55.

    PubMed  PubMed Central  Google Scholar 

  131. 131.

    Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71(8):3162–72.

    CAS  PubMed  Article  Google Scholar 

  132. 132.

    van Roosmalen W, Le Devedec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, et al. Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. J Clin Investig. 2015;125(4):1648–64.

    PubMed  PubMed Central  Article  Google Scholar 

  133. 133.

    Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 2013;73(10):3155–67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  134. 134.

    D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, et al. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015;75(21):4651–64.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  135. 135.

    Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, et al. Tissue factor induced by epithelial-mesenchymal transition triggers a procoagulant state that drives metastasis of circulating tumor cells. Cancer Res. 2016;76(14):4270–82.

    PubMed  Article  Google Scholar 

  136. 136.

    Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, et al. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008;22(3):308–21.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  137. 137.

    Chen J, Chen Z, Chen M, Li D, Li Z, Xiong Y, et al. Role of fibrillar Tenascin-C in metastatic pancreatic cancer. Int J Oncol. 2009;34(4):1029–36.

    CAS  PubMed  Article  Google Scholar 

  138. 138.

    Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006;25(56):7434–9.

    CAS  PubMed  Article  Google Scholar 

  139. 139.

    Xu SH, Huang JZ, Xu ML, Yu G, Yin XF, Chen D, et al. ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling. J Pathol. 2015;236(2):175–85.

    CAS  PubMed  Article  Google Scholar 

  140. 140.

    Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Furst K, et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell. 2013;24(4):512–27.

    CAS  PubMed  Article  Google Scholar 

  141. 141.

    Wu Z, Wei D, Gao W, Xu Y, Hu Z, Ma Z, et al. TPO-Induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110 + tumor-initiating cells. Cell Stem Cell. 2015;17(1):47–59.

    CAS  PubMed  Article  Google Scholar 

  142. 142.

    Addison JB, Koontz C, Fugett JH, Creighton CJ, Chen D, Farrugia MK, et al. KAP1 promotes proliferation and metastatic progression of breast cancer cells. Cancer Res. 2015;75(2):344–55.

    CAS  PubMed  Article  Google Scholar 

  143. 143.

    Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.

    CAS  PubMed  Article  Google Scholar 

  144. 144.

    Wu X, Zhang W, Font-Burgada J, Palmer T, Hamil AS, Biswas SK, et al. Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci USA. 2014;111(38):13870–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  145. 145.

    Razidlo GL, Magnine C, Sletten AC, Hurley RM, Almada LL, Fernandez-Zapico ME, et al. Targeting pancreatic cancer metastasis by inhibition of Vav1, a driver of tumor cell invasion. Cancer Res. 2015;75(14):2907–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F, et al. VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients. Proc Natl Acad Sci USA. 2015;112(22):E2900–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  147. 147.

    Zelenko Z, Gallagher EJ, Tobin-Hess A, Belardi V, Rostoker R, Blank J, et al. Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression. Oncogene. 2016. doi:10.1038/onc.2016.305.

    PubMed  Google Scholar 

  148. 148.

    Teng Y, Ren MQ, Cheney R, Sharma S, Cowell JK. Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. Br J Cancer. 2010;103(7):1066–75.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  149. 149.

    Qin L, Yin YT, Zheng FJ, Peng LX, Yang CF, Bao YN, et al. WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis. Oncotarget. 2015;6(12):10239–52.

    PubMed  PubMed Central  Article  Google Scholar 

  150. 150.

    Cao J, Wang Y, Dong R, Lin G, Zhang N, Wang J, et al. Hypoxia-Induced WSB1 promotes the metastatic potential of osteosarcoma cells. Cancer Res. 2015;75(22):4839–51.

    CAS  PubMed  Article  Google Scholar 

  151. 151.

    El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TG, Negri GL, Somasekharan SP, et al. Translational activation of HIF1alpha by YB-1 promotes sarcoma metastasis. Cancer Cell. 2015;27(5):682–97.

    CAS  PubMed  Article  Google Scholar 

  152. 152.

    Si W, Huang W, Zheng Y, Yang Y, Liu X, Shan L, et al. Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell. 2015;27(6):822–36.

    CAS  PubMed  Article  Google Scholar 

Download references

Authors’ contributions

Study conception and design: CNQ; acquisition of data: YM and JPY; analysis and interpretation of data: YM, JPY and CNQ; drafting of manuscript: YM and CNQ. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81272340, No. 81472386, No. 81672872), the National High Technology Research and Development Program of China (863 Program) (No. 2012AA02A501), the Science and Technology Planning Project of Guangdong Province, China (No. 2014B020212017, No. 2014B050504004 and No. 2015B050501005), and the Natural Science Foundation of Guangdong Province, China (No. 2016A030311011).

Competing interests

The authors declare that they have no competing interests.

Author information

Affiliations

  1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China

    Yan Mei, Jun-Ping Yang & Chao-Nan Qian

  2. Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China

    Chao-Nan Qian

Authors
  1. Yan Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-Ping Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chao-Nan Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chao-Nan Qian.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mei, Y., Yang, JP. & Qian, CN. For robust big data analyses: a collection of 150 important pro-metastatic genes. Chin J Cancer 36, 16 (2017). https://doi.org/10.1186/s40880-016-0178-z

Download citation

Keywords

  • Pro-metastatic gene
  • Big data analysis
  • Renal cancer
  • Liver cancer

Cancer Communications

ISSN: 2523-3548

Contact us